Towards tailored radiopeptide therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 8, 2015, Pages 1231-1237

  Radojewski, Piotr ^a   Dumont, Rebecca ^b,c   Marincek, Nicolas ^a,b   Brunner, Philippe ^b   Mäcke, Helmut R ^b   Müller Brand, Jan ^b   Briel, Matthias ^d   Walter, Martin A ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Metabolic therapy; sstr2; Survival; Targeted therapy

Indexed keywords

EDOTREOTIDE LU 177; EDOTREOTIDE Y 90; RADIOISOTOPE; 177LU-OCTREOTIDE, DOTA(0)-TYR(3)-; 90Y-OCTREOTIDE, DOTA-TYR(3)-; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; DRUG UPTAKE; FEMALE; HUMAN; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; RADIOISOTOPE THERAPY; RISK ASSESSMENT; THROMBOCYTOPENIA; AGED; ANALOGS AND DERIVATIVES; EVALUATION STUDY; NEUROENDOCRINE TUMORS; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS;

EID: 84932199950     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3030-9     Document Type: Article

References (10)

1. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416–23. doi:10.1200/JCO.2010.33.7873.
2. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47(9):1467–75.
3. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32(2):133–40. doi:10.1053/snuc.2002.31027.
4. Oyen WJ, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M, et al. Targeted therapy in nuclear medicine – current status and future prospects. Ann Oncol. 2007;18(11):1782–92. doi:10.1093/annonc/mdm111.
5. Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012;30(10):1100–6. doi:10.1200/JCO.2011.37.2151.
6. Romer A, Seiler D, Marincek N, Brunner P, Koller MT, Ng QK, et al. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(2):214–22. doi:10.1007/s00259-013-2559-8.
7. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
8. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847–56. doi:10.1007/s00259-008-0778-1.
9. Kashyap R, Jackson P, Hofman MS, Eu P, Beauregard JM, Zannino D, et al. Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. Eur J Nucl Med Mol Imaging. 2013;40(12):1853–60. doi:10.1007/s00259-013-2504-x.
10. Sierra ML, Agazzi A, Bodei L, Pacifici M, Arico D, De Cicco C, et al. Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC. Cancer Biother Radiopharm. 2009;24(6):659–65. doi:10.1089/cbr.2009.0641.